Health ProductsDear Healthcare Professional Letter

Phenytoin Sodium Injection USP 50 mg/mL - Potential for Particulate Matter in 2 mL and 5 mL Vials - For Health Professionals

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs
Issue: Quality
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Sandoz Canada Inc. Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Health Canada Endorsed Important Safety Information on Phenytoin Sodium Injection USP 50 mg/mL

December 19, 2013

Dear Health Care Professional;

Subject: Potential for Particulate Matter in 2 mL and 5 mL Vials of Phenytoin Sodium Injection USP 50 mg/mL (DIN: 00780626, Product Codes: 44000553 (6200) and 44000554 (6211))

Sandoz Canada Inc., in consultation with Health Canada, would like to inform you of the possible presence of particulate matter in some vials (2 mL and 5 mL size) of Phenytoin Sodium Injection USP 50 mg/mL. Low levels of sub-visible particulate matter, determined to be inert carbon related to the vial manufacturing process, have been noted during a recent investigation. Particulate matter has not been observed in the listed lots of Phenytoin Sodium Injection USP which have been released onto the Canadian market.  Furthermore, the listed lots met all standards for particulate matter (visible and sub-visible) prior to release onto the Canadian market, and those lots monitored on routine stability continue to meet these standards.  However, the possible presence of visible particulate matter in these lots cannot be excluded.  A list of potentially affected lots is attached (Appendix A).

  • Inadvertent injection of particulate matter into a patient could result in patient injury, such as local inflammation, phlebitis, allergic response and/or embolization in the body.
  • As per standard practice, carefully inspect all phenytoin injectable products before use (or after dilution).  As Phenytoin Sodium Injection USP may precipitate following dilution, inspect for presence of particulate matter or haziness of the solution after dilution.  Should visible particulate matter be observed, do not administer.
  • The use of a 0.22 micron in-line filter is recommended when administering the listed lots of Phenytoin Sodium Injection USP (see Appendix A).
  • Where it is not possible to use an in-line filter for intravenous administration, alternative therapies should be considered.

Phenytoin Sodium Injection USP is indicated for control of tonic-clonic (grand mal) and psychomotor or partial (focal) seizures as well as for the prevention and treatment of seizures occurring during neurosurgery. Phenytoin Sodium Injection USP is approved for direct intravenous injection and for intramuscular administration.Footnote 1

Intravenous treatment should be reserved for use only in those patients who cannot be treated with oral phenytoin. Oral therapy should replace parenteral administration as soon as possible.Footnote 1 Precipitation of free phenytoin may occur at pH 11.5 or less. The mixing of phenytoin sodium with other drugs or with intravenous infusion solutions may result in crystallization or precipitation if the drug product in the vial has been kept in a refrigerator or freezer, or the pH is lowered.Footnote 2

Since the release of the potentially affected lots of Phenytoin Sodium Injection USP, no adverse event reports related to this issue were received at Sandoz Canada Inc. Any Sandoz phenytoin vial with evidence of visible particulates should not be used and should be reported to Sandoz Canada.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-market adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any cases of serious adverse reaction or unexpected adverse reactions in patients receiving Phenytoin Sodium Injection USP should be reported to Sandoz Canada Inc. or Health Canada.

Sandoz Canada Inc,
145 Jules Léger
Boucherville, Quebec, Canada
J4B 7K8
Tel: 1-800-343-8839 ext. 4636
Fax: 1-888-243-6221

To correct your mailing address or fax number, contact Sandoz Canada Inc.

You can report any suspected adverse reactions associated with the use of health products to Health Canada by: 

  • Calling toll-free at 1-866-234-2345; or
     
  • Visiting MedEffect Canada's Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax

For other health product inquiries related to this communication, contact Health Canada at:
Health Products and Food Branch Inspectorate (HPFBI)
E-mail: DCVIU_UVECM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 1-613-946-5636

If you have questions regarding the above information, please contact our Drug Information Department at 1-800-343-8839 (4636). 

Sincerely,

original signed by

Michèle Théberge
Vice-President, Quality Unit

original signed by

Len Arsenault
Vice-President, Scientific Affairs

References

Footnote 1

Sandoz Canada Inc., Phenytoin Sodium Injection USP, Prescribing Information, revised April 10, 2013.

Return to footnote 1 referrer

Footnote 2

Handbook on Injectable Drugs, accessed on 12-Dec-2013

Return to footnote 2 referrer

Encl.  Appendix A

APPENDIX A
Material Material Description Batch Expiry Date
44000554 PHENYTOIN NA 50MG/ML 5ML 10LIVI CA BT9159 2013-12-31
CG2519 2014-08-31
CH9389 2014-09-30
CK9567 2014-10-31
CX9724 2015-04-30
DA2448 2015-06-30
DE5293 2015-08-31
44000553 PHENYTOIN NA 50MG/ML 2ML 10LIVI CA BG1193 2013-12-31
BL9015 2014-03-31
CB1255 2014-11-30
CG0113 2015-02-28
CJ8539 2015-04-30
CN3870 2015-06-30
DA4554 2015-12-31
DE2788 2016-02-29
DP2639 2016-07-31

 

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime